



(12) Translation of
European patent specification

(11) NO/EP 2970460 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.09.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.04.29
(86)	European Application Nr.	14722008.1
(86)	European Filing Date	2014.03.12
(87)	The European Application's Publication Date	2016.01.20
(30)	Priority	2013.03.13, US, 201361778687 P 2013.05.03, US, 201361819018 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
(72)	Inventor	MURPHY, Andrew, J., 10 Newton Court, Croton-on-Hudson, NY 10520, USA PAPADOPOULOS, Nicholas, J., 59 Heritage Lane, Lagrangeville, NY 12540, USA ORENGO, Jamie, M., 17 Maple Moor Lane, Cortlandt Manor, NY 10567, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **ANTI-IL-33 ANTIBODIES AND USES THEREOF**

(56) References
Cited: WO-A2-2005/079844
Anonymous: "AnaptysBio Announces Development of Novel Anti-IL33 Therapeutic Antibody | AnaptysBio", , 10 January 2014 (2014-01-10), XP055126733, Retrieved from the Internet: URL:<http://www.anaptysbio.com/anti-il33/> [retrieved on 2014-07-03]
Uniprot: "Alignment human and cynomolgus monkey IL-33", , 3 August 2017 (2017-08-03), XP055396027, Retrieved from the Internet: URL:<http://www.uniprot.org/align/A20170803AAF7E4D2F1D05654627429E83DA5CCEC7E4343> [retrieved on 2017-08-03]
MINGCAI LI ET AL: "IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 247, no. 1, 19 March 2012 (2012-03-19), pages 25-31, XP028486570, ISSN: 0165-5728, DOI: 10.1016/J.JNEUROIM.2012.03.016 [retrieved on 2012-03-25]
FOO Y LIEW ET AL: "Disease-associated functions of IL-33: the new kid in the IL-1 family", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol.

10, no. 2, 1 February 2010 (2010-02-01), pages 103-110, XP002658775, ISSN: 1474-1741, DOI: 10.1038/NRI2692 [retrieved on 2010-01-18]

R. KAMEKURA ET AL: "The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis", CLINICAL & EXPERIMENTAL ALLERGY : JOURNAL OF THE BRITISH SOCIETY FOR ALLERGY AND CLINICAL IMMUNOLOGY, vol. 42, no. 2, 1 February 2012 (2012-02-01), pages 218-228, XP055510079, UK ISSN: 0954-7894, DOI: 10.1111/j.1365-2222.2011.03867.x & Anonymous: "Human ST2/IL-33 R Antibody Monoclonal Mouse IgG1 Clone # 97203 Catalog Number: MAB523", , 26 September 2018 (2018-09-26), XP055510080, Retrieved from the Internet: URL:https://resources.rndsystems.com/pdfs/datasheets/mab523.pdf [retrieved on 2018-09-26]

PALMER GABY ET AL: "Interleukin-33 biology with potential insights into human diseases", NATURE REVIEWS. RHEUMATOLOGY, NATURE PUBL. GROUP, USA, vol. 7, no. 6, 1 June 2011 (2011-06-01), pages 321-329, XP009178467, ISSN: 1759-4804

H. HAYAKAWA ET AL: "Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 36, 1 January 2007 (2007-01-01), pages 26369-26380, XP055030354, ISSN: 0021-9258, DOI: 10.1074/jbc.M704916200

PALMER G ET AL: "The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 42, no. 3, 1 June 2008 (2008-06-01), pages 358-364, XP022696634, ISSN: 1043-4666, DOI: 10.1016/J.CYTO.2008.03.008 [retrieved on 2008-05-02]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

2970460

Patentkrav

1. Humant monoklonalt antistoff eller antigenbindende fragment derav for anvendelse i en fremgangsmåte for behandling av kronisk astma hos en pasient med behov for dette, hvor fremgangsmåten omfatter å administrere, til pasienten,
5 et antistoff eller et antigenbindende fragment derav som binder humant interleukin 33 (IL-33), og omfatter en variabel tungkjederegion (HCVR) omfattende aminosyresekvensen av SEQ ID NO: 274 og en variabel lett kjederegion (LCVR) omfattende aminosyresekvensen av SEQ ID NO: 282.
- 10 2. Humant monoklonalt antistoff eller antigenbindende fragment derav for anvendelse i en fremgangsmåte for behandling av kronisk obstruktiv lungesykdom (COPD) hos en pasient med behov for dette, hvor fremgangsmåten omfatter å administrere, til pasienten, et antistoff eller et antigenbindende fragment derav som binder humant interleukin 33 (IL-33), og omfatter en variabel tungkjederegion
15 (HCVR) omfattende aminosyresekvensen av SEQ ID NO: 274 og en variabel lett kjederegion (LCVR) omfattende aminosyresekvensen av SEQ ID NO: 282.
3. Antistoff eller antigenbindende fragment for anvendelse ifølge krav 2, hvor COPD-en skyldes, eller er delvis forårsaket av, aktiv eller passiv sigarett røyking.
- 20 4. Antistoff eller antigenbindende fragment for anvendelse ifølge et hvilket som helst av kravene 1 til 3, hvor fremgangsmåten videre omfatter å administrere en effektiv mengde av et andre terapeutisk middel som er nyttig for lindring av den kroniske astma eller COPD-en, valgfritt hvor det andre terapeutiske middel velges fra
25 gruppen bestående av et ikke-steroidalt antiinflammatorisk middel (NSAID), et kortikosteroid, en bronkiedilator, et antihistamin, epinefrin, et middel mot kongestion, en thymisk stromal lymfopoietin (TSLP)-antagonist, en IL-13-antagonist, en IL-4-antagonist, en dual IL-4/IL-13-antagonist, en IL-5-antagonist, en IL-6-antagonist, en IL-12/23-antagonist, en IL-22-antagonist, en IL-25-antagonist,
30 en IL-17-antagonist, en IL-31-antagonist, en oral PDE4-hemmer og en annen IL-33-antagonist eller et annerledes antistoff mot IL-33.

2970460

5. Humant antiklonalt antistoff for anvendelse ifølge et hvilket som helst av kravene 1 til 4, som er et IgG1-antistoff.

6. Humant antiklonalt antistoff for anvendelse ifølge et hvilket som helst av kravene 1 til 4, som er et IgG4-antistoff.